Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19

Summary

It is hypothesized that immunotherapy with off-the-shelf NK cells (KDS-1000) early in the course of COVID-19 disease is safe and may augment innate immunity, thereby limiting disease progression and improving survival.

Timeline

Start

2020-12

Primary completion

2021-04

Completion

2021-04

Outcome

Outcome not reported

Stopped: “The sponsor decided to withdraw this study”

Drugs

Indications